CRESCO LABS INC. WKN: A2PAHM ISIN: CA22587M1068 Kürzel: CRLBF Forum: Aktien Thema: Hauptdiskussion

Tiefer wie 9,30 wird’s nichtmehr gehen. Jetzt geht es AUFWÄRTS!

Ja da kommt noch einiges. Cresco beinhaltet 25% meines Depots.

Also ich muss echt sagen cresco top,besser geht nicht. Da kommt noch einiges,oder?👍😎

👍🙏

CHICAGO, 01. Februar 2021 –(BUSINESS WIRE)–Cresco Labs (CSE:CL) (OTCQX:CRLBF) ("Cresco" oder "das Unternehmen"), einer der größten vertikal integrierten Cannabis-Betreiber in den Vereinigten Staaten, gab heute bekannt, dass es die Genehmigung des Arizona Department of Health Services erhalten hat, um Kunden mit Erwachsenennutzung in seiner Sunnyside-Dispensary in Phoenix zu bedienen. Das Unternehmen wird voraussichtlich Mitte Februar den Verkauf von Erwachsenen-Nutzungen starten. Am 22. Januar war Arizona der 12. Bundesstaat, der damit begann, Cannabis-Kunden mit Erwachsenenkonsum zu bedienen, nachdem eine Mehrheit der Einwohner im vergangenen November für den Vorschlag gestimmt hatte. Als Unternehmen ist es unsere Strategie, unsere Ressourcen nur in den strategischsten Märkten mit entsprechenden Vorschriften und einer starken Verbrauchernachfrage zu investieren. In den letzten 10 Jahren hat Arizona nicht nur ein verantwortungsvolles medizinisches Cannabis-Programm verabreicht, sondern auch eine starke Beteiligung mit mehr als 300.000 aktiven Patienten.

....geht heute schön gleichmäßig nach oben 🤭

Supi nur noch etwas mehr grün. Super Artikel Danke.👍😎

https://www.newcannabisventures.com/cresco-labs-to-launch-adult-use-sales-at-sunnyside-dispensary-in-phoenix-arizona/

Hab Freitag nachgelegt. Toller Artikel top Invest.👍😎

Why you should buy it In my mind, there are several strong reasons to buy this stock. First, Cresco's quarterly revenue is growing explosively at a rate of 326.6% year over year. Growth like that could ebb over the next year and easily remain in the triple-digits. It's growing so rapidly because it's already the largest cannabis wholesaler in the American market. The company derives 59% of its revenue from wholesale transactions, which is significantly more than its primary competitors like Curaleaf. As the rest of the industry expands market penetration in the form of retail locations, Cresco keeps pace by benefiting from economies of scale. Management is committed to maintaining its lead in wholesaling in the long term because that's where they think margins will be the highest. It's clear that the strategy is working -- so far. Speaking of margins, management has also pushed forward with selling, general, and administrative (SG&A) cost cuts and other helpful improvements. In particular, its cultivation facilities in Illinois and Pennsylvania are becoming more efficient quite rapidly. Management credits the efficiency improvements at these facilities in particular for an improvement in operational gross profit as a percentage of revenue coming in at 53% in the quarter, compared to 47% in the previous quarter. Most importantly, thanks to falling costs and rising revenue, the company's most recent adjusted earnings before interest, taxes, amortization, and depreciation (EBITDA) of $46.4 million are the largest it has ever reported. Its $17.8 million in cash flow from operations is also a company record. Why it might be better to wait Even though its core financial metrics are improving rapidly, Cresco is still unprofitable, with a negative profit margin of 17.88%. But compared to companies like Aurora Cannabis, it's much closer to consistently profitable operations. Unfortunately, management hasn't provided any explicit estimates for when profitability might occur. My estimate, based on the last few quarters of data, is that it might be profitable by the end of 2021, which is a bit far in the future for conservative investors looking to make a decision today. Furthermore, Cresco competes in the medicinal and recreational cannabis markets, but its portfolio of adult use brands is far larger than its medicinal holdings. As the marijuana industry experiences rising business competition from a wave of legalization in the U.S., it may not be able to defend its medicinal market share against others as a result. This is especially concerning because it enjoys a higher price point with its Remedi medicinal brand in comparison to its adult-use brands like Good News and its newest brand, High Supply. If the price is right for medicinal cannabis, why does management continue to advance with lower-price and less-differentiated brands?

News?

Boden gefunden ?

Hab nachgelegt. Schon vorm aktionär auch von Foohl empfohlen.

Seit der aktionärs empfehlung gings berg ab🤦‍♂️ super👍

Toller Hot Stok

stay long....